Objective-The immune receptor homologue glycoprotein VI (GPVI)/FcR receptor ␥ chain complex is primarily responsible for platelet activation by collagen. There is growing evidence that optimal binding of GPVI to collagen depends on the assembly of GPVI dimers. The valence of GPVI on resting platelets needs to be clearly established because platelet avidity for collagen would be greater if GPVI is constitutively expressed as a dimer than as a monomer. Methods and Results-Using a monoclonal antibody (9E18) that preferentially binds to GPVI dimers, we found that GPVI was maintained in a monomeric form on human resting platelets under the control of intraplatelet cAMP concentration. Activation by soluble agonists or von Willebrand factor induced a shift toward GPVI dimerization related to increased platelet adhesion to collagen. A correlation between platelet binding of 9E18 and P-selectin exposure was observed in patients experiencing coronary artery disease, and antagonists of the ADP receptor P2Y 12 limited ADP-induced GPVI dimerization. Conclusion-The rapid assembly of highly competent dimers of GPVI at sites of vascular lesion represents an important step in the sequence of events leading to platelet activation by collagen. GPVI dimers could represent a new marker to analyze platelet reactivity. (Arterioscler Thromb Vasc Biol. 2012;32:778-785.) -P.) and Département de Cardiologie (L.F.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
P latelet adhesion at sites of vascular damage is required for normal hemostasis. Circulating platelets adhere to proteins of the subendothelial matrix exposed by vessel injury in a process involving several receptors. Collagen fibers are highly thrombogenic, and the platelet glycoprotein VI (GPVI) predominantly mediates collagen-induced platelet responses.
GPVI is a platelet-specific receptor of the immunoglobulin (Ig) superfamily containing 2 extracellular Ig domains, a single transmembrane domain, and a short cytoplasmic tail. [1] [2] [3] GPVI shares with other receptors of the same family the particularity that the extracellular ligand-binding domain and the intracellular signaling domain are on separate subunits. GPVI signals through the noncovalently associated immune receptor adaptor FcR␥. 4 The receptor is assembled via a transmembrane interaction between Asp11 in the FcR␥ homodimer and Arg273 of GPVI. On stimulation, the Tyr residues of the immunoreceptor tyrosine-based activation motif of FcR␥ are phosphorylated in an early, obligatory event triggering the signaling cascade.
See accompanying article on page 552
There is growing evidence that optimal binding of GPVI to collagen depends on the formation of GPVI dimers at the platelet surface. Miura et al, 5 using recombinant proteins, were the first to report that collagen binds to the dimeric form but not to the monomeric form of GPVI and that only the former was able to inhibit collagen-induced platelet activation. Crystallographic data showing dimerization of GPVI ectodomains, 6 studies using synthetic peptides with differentially spaced GPVI binding motifs to activate the receptor in platelets, 7 and studies using chemical cross-linking agents 8 have strongly reinforced the notion that GPVI functions as a dimer. However, the valence of GPVI on resting and on activated platelets is still a matter of debate. It was recently proposed that at least some copies of GPVI may exist in a dimeric conformation at the surface of resting platelets. 9 The extent of GPVI dimerization is important to determine because it is expected that platelet avidity for collagen would be greater if GPVI was constitutively expressed as a dimer than as a monomer.
We have obtained an anti-human GPVI monoclonal antibody 9E18 that binds to dimeric GPVI with an affinity at least 200-fold higher than to monomeric GPVI. Using 9E18, we provide evidence that most of GPVI is maintained in a monomeric form on resting platelets under the control of intraplatelet cAMP and that GPVI dimerization occurs in response to soluble agonists and to von Willebrand factor (vWF)-induced platelet activation. Interestingly, in a population of coronary artery disease (CAD) patients, a good correlation between 9E18 binding and P-selectin exposure was observed. Furthermore, ADP-induced 9E18 binding to platelets was prevented in patients treated by thienopyridines.
In conclusion, binding of 9E18 to platelets is an indicator of GPVI dimerization and could represent a new biomarker of early platelet reactivity and responsiveness to P2Y 12 antagonists.
Materials and Methods
Detailed methods available in the online-only Data Supplement.
Antibodies
The anti-human GPVI monoclonal antibodies 3J24 and 9E18 were obtained as previously described. 2, 10 They are not activating antibodies, as purified IgGs do not trigger P-selectin exposure on platelets. 3J24 and 9E18 bind to different epitopes. 10 The 9E18 IgG is able to inhibit GPVI binding to collagen, 10 but its Fab is far less inhibitory than the 9O12 Fab on collagen-induced platelet activation. 2, 11, 12 
Reagents
Collagen from equine tendon (Horm collagen) was from Nycomed (Munich, Germany). Convulxin was purified from the venom of Crotalus durissus terrificus. 13 Recombinant soluble GPVI was obtained as the extracellular domain of human GPVI fused to the Fc domain of human Igs (GPVI-Fc that is dimeric) 1 or fused to a poly-His tag (GPVI-His that is monomeric). Their K Dapp for collagen were respectively 1.13Ϯ0.03 g mL Ϫ1 (5Ϯ0.2 nmol/L) and 14.7Ϯ3.3 g mL Ϫ1 (270Ϯ54 nmol/L), in agreement with published data. 5, 14 Monomeric GPVI was also obtained by reduction of GPVI-Fc.
Binding Assays Using Purified Proteins
Experiments were conducted mainly as previously described. 14 Increasing amounts of purified GPVI-Fc and GPVI-His were incubated in 9E18-coated wells and detected using horseradish peroxidase-coupled anti-human IgG and anti-6ϫHis, respectively.
Isolation of Platelets
Blood was obtained from healthy volunteers who had not taken medication for 10 days, after full informed consent was obtained according to the Declaration of Helsinki. Platelet-rich plasma (PRP) and platelet poor plasma were obtained by centrifugation of citrated blood. Alternatively, blood was collected on acid-citrate-dextrose anticoagulant to prepare washed platelets as previously reported. 15
Platelet Adhesion and Activation
Platelet adhesion to immobilized collagen in static conditions was measured as described. 11 Platelets activated by ADP, thrombin receptor activating peptide (TRAP), epinephrine, or phorbol 12-myristate 13-acetate (PMA) were analyzed by flow cytometry after incubation with fluorescein isothiocyanate-coupled anti-GPVI or P-selectin antibodies. Alternatively, shear-induced platelet activation was performed as previously described. 16 Phosphorylation of vasodilatator-stimulated phosphoprotein was measured by quantitative flow cytometry. Resistance to clopidogrel was defined by a P2Y 12 reactivity ratio Ͼ50%. 17
Immunoblotting
Proteins from whole platelet lysates were separated by electrophoresis in SDS-polyacrylamide gels and analyzed by immunoblotting using anti-GPVI antibodies and secondary horseradish peroxidase-coupled IgG. 1
Patients
Blood samples were obtained from a cohort of patients with CAD referred to the department of cardiology of Bichat hospital for percutaneous coronary intervention (BIOCORE-2 study; clinical trial registration: http://clinicaltrials.gov/ct2/show/NCT01186666? termϭNCT01186666&rankϭ1). The study complies with the Declaration of Helsinki and was approved by the institutional ethics committee. All of the patients provided written informed consent. The patients were treated with dual antiplatelet therapy consisting of aspirin and an antagonist of the P2Y 12 receptor, at the discretion of the cardiologist. Blood was drawn on 0.109 mol/L citrate the day after percutaneous coronary intervention. Fluorescence-activated cell sorting analysis was performed on PRP prepared less than 1 hour after blood sampling using fluorescein isothiocyanate-coupled 9E18, 3J24, or anti-P-selectin. Controls were healthy subjects who had taken no medication during the 2 previous weeks.
Statistics
Data were analyzed using PRISM (GraphPad, San Diego, CA). Box plots represent means, minimal, and maximal values. Statistical analysis included the paired Student t test (2-tailed) and the Mann-Whitney test (2-tailed). Correlations were determined using linear regression and Spearman 2-tailed analysis.
Results

9E18 Discriminates Dimeric From Monomeric GPVI
In preliminary experiments, 9E18 IgG were found to bind poorly to GPVI-His (monomeric GPVI) as compared with another anti-GPVI IgG, 3J24. We thus characterized the interaction of dimeric and monomeric GPVI with 9E18 in binding experiments ( Figure 1A ). Binding of GPVI-Fc to immobilized 9E18 was saturable, allowing calculation of an affinity constant (K d ϭ0.36 nmol/L). In contrast, GPVI-His hardly bound to 9E18, and saturation was not reached. The best estimated K d was 78 nmol/L, indicating that the affinity of dimeric GPVI for 9E18 is at least 200-fold higher than the affinity of monomeric GPVI. Furthermore, in competition experiments, soluble GPVI-Fc efficiently inhibited 9E18 binding to immobilized GPVI-Fc, whereas GPVI-His and reduced GPVI-Fc were much less efficient ( Figure I in the online-only Data Supplement), confirming that the affinity of 9E18 for monomeric GPVI is far lower than for dimeric GPVI.
Immunoblotting confirmed the poor capacity of 9E18 to detect GPVI-His or reduced GPVI-Fc ( Figure 1B and Figure  I in the online-only Data Supplement). 9E18 thus permits discrimination between GPVI dimers and momomers.
Binding of 9E18 to Resting Platelets
By flow cytometry, a very low level of 9E18 binding to platelets was observed in whole blood as compared with the level of GPVI labeled by 3J24 ( Figure 1C ). Interestingly, the basal level of 9E18 binding to platelets increased progres-sively from whole blood to PRP and washed platelets (2.25Ϯ0.7% [nϭ7], 3.1Ϯ2.4% [nϭ36], and 14Ϯ1.6% [nϭ20] positive platelets, respectively). Furthermore, GPVI was poorly detected using 9E18 on a whole platelet lysate ( Figure 1D ).
Binding of 9E18 to Activated Platelets
3J34 bound equally well to washed platelets treated with TRAP-1 or ADP as to resting platelets (80Ϯ3% and 91Ϯ4% versus 85.5Ϯ3%) ( Figure 2A ). In contrast, binding of 9E18 significantly increased from 14Ϯ1.6% to 36.2Ϯ7% on TRAP-activated washed platelets and, to a lesser extent (25Ϯ5%), on ADP-activated platelets. Both agonists also induced surface exposure of P-selectin. All 9E18-positive events were also P-selectin-positive. There was no aggregation in these conditions. A similar increase in 9E18 binding to stimulated platelets was observed in whole blood ( Figure 2B ). Epinephrine (0.5 mol/L) increased the binding of 9E18 to platelets by a factor of 1.5, and this effect was additive with the effect of ADP (data not shown). The IV.3 monoclonal antibody did not prevent 9E18 binding to activated platelets, ruling out a nonspecific binding of 9E18 to Fc␥RIIA ( Figure  II in the online-only Data Supplement). Furthermore, binding of 9E18 to stimulated platelets was specifically and dosedependently inhibited by GPVI dimers and not by monomers ( Figure 2C ). In addition, even after platelet activation, 9E18 still poorly detected the 58-kDa band corresponding to monomeric GPVI ( Figure 2D ).
Together, these data indicate that 9E18 recognizes an epitope exposed by GPVI dimers whose formation is an activation-dependent event.
Shear-Induced Binding of the 9E18 Antibody
The initial interaction of GPIb with vWF, assumed to slow down platelets and to favor GPVI interaction with collagen, was triggered in vitro by high shear stress 18 ( Figure 3A) . 9E18 binding increased from 3.6Ϯ1.6% after 5 minutes at 0 s Ϫ1 to 7Ϯ2% at 4000 s Ϫ1 (PϽ0.05 nϭ3). Interestingly, although the number of 9E18-positive events was low in the gate corresponding to isolated platelets (2.7Ϯ0.4%), it was increased to 26Ϯ7.7% in the gate focused on shear-induced aggregates. Experiments performed with a control mouse IgG ruled out any nonspecific trapping in shear-induced platelet aggregates. When experiments were repeated on washed platelets, the addition of vWF induced a parallel increase in shear-induced platelet aggregation and in the level of 9E18 binding ( Figure 3B ). P-selectin exposure was also observed on platelet aggregates.
Platelet Adhesion to Collagen
To investigate whether binding of 9E18 was related to the capacity of platelets to interact with collagen, 9E18 binding and GPVI-specific platelet attachment to collagen were measured in parallel, after ␣ IIb ␤ 3 and ␣ 2 ␤ 1 integrins were blocked by the addition of RGDS and the absence of Mg 2ϩ . A significant linear correlation was observed between binding of 9E18 and the adhesion to collagen (r 2 ϭ0.87, Pϭ0.0002, nϭ9), indicating that the conformation of GPVI recognized by 9E18 is favorable for GPVI-dependent platelet adhesion to collagen ( Figure 3C ).
Mechanisms Leading to Activation-Dependent Changes in GPVI
As binding of 9E18 to platelets was induced by receptor activation, we examined whether it could be induced independently of a cell surface receptor and found that PMA increased the level of 9E18 binding to platelets up to 31.5Ϯ4% (PϽ0.001) ( Figure 4 ). cAMP is established as limiting platelet activation. Adenylate cyclase is inhibited by ADP activation of its receptor P2Y 12 and activated by prostacyclin. Whereas ADP increased the binding of 9E18, PGE1 reduced it on washed resting platelets, as well as on TRAP-, ADP-, or PMA-activated platelets ( Figure 4A ). Forskolin and IBMX induce a receptorindependent elevation of cAMP via the direct activation of adenylate cyclase and the inhibition of phosphodiesterase, respectively. Forskolin plus IBMX ( Figure 4A ) and even forskolin alone (data not shown) inhibited 9E18 binding to resting, or ADP-, TRAP-, or PMA-activated platelets.
NO donors that increase intraplatelet cGMP concentration are also inhibitors of platelet activation; the NO donor SNAP inhibited 9E18 binding to resting platelets, as well as to TRAP-, ADP-, or PMA-activated platelets ( Figure 4A ).
The role of endogenous platelet agonists in 9E18 binding to platelets was analyzed. Indomethacin had no effect on the level of 9E18 binding to stimulated platelets, ruling out a role of TXA2. In contrast, apyrase inhibited both ADP-and Binding of 9E18 to glycoprotein VI (GPVI). A, Increasing amounts of soluble GPVI-Fc (circles) or GPVI-His (squares) were incubated in 9E18 IgG-coated microtitration wells and detected using horseradish peroxidase-coupled mouse antihuman Fc specific and anti-6ϫHis. Data are the means of triplicates from 1 representative experiment. B, Purified GPVI-Fc and GPVI-His (1 g) were immunoblotted with 9E18 or 3J24 (loading control) (2 g/mL). C, Whole blood was incubated with 4 g/mL fluorescein isothiocyanate-coupled 3J24 (in blue), 9E18 (in red), or a mouse IgG1 (in black) as isotypic control, and fluorescence was acquired in the platelet gate. Data are from 1 typical experiment out of 20. D, Detection of GPVI in whole platelet lysates (5 or 10 g proteins) by immunoblotting with 9E18 or 3J24 (2 g/mL). 3J24 and Ponceau red were the loading controls.
TRAP-induced binding of 9E18 by 85% and 75%, respectively, indicating that released ADP contributes to GPVI changes. The P2Y 12 antagonist 2MeSAMP also inhibited 9E18 binding to ADP-or TRAP-stimulated platelets (data not shown).
Phenylarsine oxide, a reagent that binds to vicinal sulfhydryls and that was previously reported to inhibit GPVIdependent platelet activation 19, 20 is commonly used at low concentrations as an inhibitor of phosphotyrosine phosphatases. It fully prevented PMA-induced binding of 9E18 to platelets and GPVI-dependent platelet adhesion to immobilized collagen but was without effect on P-selectin exposure ( Figure III in the online-only Data Supplement).
In contrast, PMA-induced binding of 9E18 remained unchanged in the presence of 20 mol/L of the Tyr kinase inhibitor PP1 (28.4 versus 27.7%). FcR␥ was not phosphorylated in conditions leading to GPVI dimerization (PMA-or ADP-activated platelets), indicating that binding of 9E18 to platelets occurs independently of signals downstream of GPVI.
Binding of 9E18 Is a Potential New Marker of Platelet Activation and Efficacy of P2Y 12 Antagonists
Because binding of 9E18 is the consequence of an active GPVI modification that favors platelet interaction with fibrillar collagen, it could represent a new circulating biomarker of platelet reactivity in patients. To test this hypothesis, 9E18 binding and P-selectin exposure were measured in PRP from CAD patients (nϭ45) participating in the BIOCORE-2 study. All patients were under dual antiplatelet therapy, aspirin (75-160 mg/day), and clopidogrel (75 mg/day). A positive correlation was observed between basal 9E18 binding and P-selectin exposure (Spearman rϭ0.568; PϽ0.0001) ( Figure 5A ). Platelet activation triggers glycoprotein VI (GPVI) dimerization. A, Washed platelets were treated with thrombin receptor activating peptide (TRAP)-1 (10 mol/L) or ADP (5 mol/L) for 20 minutes before measurement of GPVI expression with fluorescein isothiocyanate (FITC)-coupled 3J24 or 9E18 and P-selectin exposure. Results are from 11 and 5 independent experiments, respectively. B, Flow cytometry analysis on whole blood of 9E18 binding to resting platelets (in black) or activated by 5 mol/L ADP (in blue) or 10 mol/L TRAP (in red). Results are from 1 representative experiment out of 5. C, Inhibition of 9E18 binding to activated platelets by recombinant soluble GPVI. Washed TRAP-activated platelets were incubated with FITC-coupled 9E18 in the presence of increasing amounts of GPVI-Fc (squares) or GPVI-His (circles). D, Whole lysates (10 g proteins) obtained from washed platelets in resting conditions or activated by ADP (10 mol/L) or TRAP (10 mol/L) for 20 minutes were immunoblotted with 9E18 or 3J24 as loading control with Ponceau red. **PϽ0.01, ***PϽ0.005.
We hypothesized that antagonists of P2Y 12 could inhibit ADP-induced 9E18 binding to platelets. To test this hypothesis, 9E18 binding to platelets was measured before and after PRP incubation with ADP in normal subjects and patients treated with clopidogrel (75 mg) ( Figure 5B) . A highly significant reduction in the response was observed in clopidogrel-treated patients. A good correlation was found between ADP-induced 9E18 binding and vasodilatator-stimulated phosphoprotein phosphorylation, which is one of the biological markers of P2Y 12 antagonists ( Figure 5C ).
Discussion
The 9E18 antibody that was raised against dimeric GPVI is characterized by its extremely poor capacity to bind to monomeric GPVI, whereas it binds to dimeric GPVI with a nanomolar affinity. This observation indicates that the antibody recognizes a specific conformational epitope on dimeric GPVI.
Several groups have reported that GPVI may form a dimer that has functional significance. 8, 9, 21, 22 X-ray crystallography of soluble GPVI revealed a dimeric conformation. 6 Furthermore, the GPVI-Fc fusion protein has demonstrated effective inhibition of thrombus formation, consistent with its ability to bind fibrillar collagen with high specificity and reasonable affinity. 1, 23 The very large discrepancy between the apparent affinities of monomeric and dimeric GPVI for fibrillar collagen suggests that the GPVI dimer acquires a specific conformation suitable for binding to collagen. The similarly large discrepancy between the apparent affinities of monomeric and dimeric GPVI for 9E18 and the observation that the level of 9E18 binding to platelets is correlated with their capacity to adhere to collagen indicate that 9E18 recognizes the conformation of the GPVI dimer favorable for binding to collagen. The capacity of 9E18 to bind to resting platelets was at the limit of the detection in fresh whole blood, indicating that GPVI is mostly monomeric on circulating platelets; the level of 9E18 binding, however, increased with platelet isolation and with time as observed for P-selectin exposure, suggesting that dimerization could be activation dependent. In fact, the observations that 9E18 specifically binds to activated platelets and that binding of 9E18 is exclusively inhibited by soluble GPVI dimers demonstrate that platelet membrane GPVI forms dimers in response to various stimuli.
GPVI has been proposed to be in a monomer-dimer equilibrium at the platelet surface, 8 and ligand binding triggered a very rapid disulfide cross-linking of the GPVI cytoplasmic domains, suggesting that some dimers may exist Fluorescence was analyzed on the whole platelet gate and in gates corresponding to isolated platelets and to shear-activated platelets. Histograms represent the meansϮSEM from 3 independent experiments. B, Washed platelets were submitted to a 4000 s Ϫ1 for 5 minutes in the absence or presence of von Willebrand factor (vWF) (50 g/mL). Platelet aggregation and binding of FITC-9E18 were measured by flow cytometry. Results are from 1 representative experiment out of 3. MFI indicates mean fluorescence intensity. C, Washed platelets from different donors stimulated by ADP (5 mol/L, circles) or thrombin receptor activating peptide (TRAP) (10 mol/L, squares) were analyzed in parallel for the binding of 9E18 by flow cytometry and allowed to adhere to immobilized collagen for 30 minutes. The increase in adherent platelets (ratio of adherent platelets in activated vs resting conditions) is plotted as a function of the increase of 9E18 binding. R 2 ϭ0.848, Pϭ0.0012. in the resting state. 21 More recently, Jung et al 9 provided evidence for the existence of a specific dimer conformation of GPVI at the platelet surface. The monoclonal antibody (204-11) is activating platelets; its monovalent recombinant m-Fab-F did not bind to GPVI monomers and bound to GPVI-Fc with a very low affinity. The authors observed a low level of m-Fab-F binding to washed platelets, suggesting the presence of some preformed dimers at the platelet surface. Here, using fluorescein isothiocyanate-9E18 with good affinity for GPVI-Fc, we showed that GPVI dimers are scarce on unstimulated platelets, particularly in whole blood. Furthermore, the fact that the binding of 9E18, and thereby the proportion of dimeric GPVI, increased after isolation of platelets suggests that the equilibrium between the monomeric and dimeric forms is easily shifted toward the latter.
We indeed observed that stimulating platelets with a weak (ADP) or a strong (TRAP) soluble agonist significantly increased the binding of 9E18, indicating that platelet stimulation brought GPVI monomers together to form dimers. The observation of a double population in ADP-or TRAPstimulated platelets but not in PMA-treated platelets indicates that regulation of GPVI dimerization depends on the agonist and possibly on the level of intracellular calcium mobilization. In agreement with the increased affinity of GPVI dimers for collagen, the initial interaction of platelets with collagen was favored in relation to the presence of dimers of GPVI at the platelet surface.
In the sequence of events assumed to result in stable platelet adhesion and aggregation, the interaction of GPIb with collagen-bound vWF is thought to precede GPVI binding to collagen. Application of a high shear to PRP triggered platelet aggregation and GPVI dimerization. Furthermore, on washed platelets, shear-induced 9E18 binding and aggregation were dependent on the presence of vWF. We thus showed for the first time that platelet activation by the vWF/GPIb axis has a priming effect on GPVI, resulting in a direct enhancement of GPVI interaction with collagen. The rapid assembly of highly competent dimers of GPVI at sites of vascular lesion represents an important and heretofore unrecognized step in the sequence of events leading to platelet activation by collagen.
The mechanism leading to GPVI dimerization is clearly distinct from the signaling cascade downstream of GPVI: it requires neither FcR␥ phosphorylation nor the activation of downstream Tyr kinases. Because the assembly of a GPVI dimer is not sufficient to trigger downstream signaling, clusters of at least 2 GPVI-dimers appear to be the minimal Figure 5 . 9E18 as a marker of platelet reactivity. A, 9E18 binding to platelets and P-selectin exposure were measured in blood samples (platelet-rich plasma [PRP]) obtained from a cohort of patients with coronary artery disease (CAD) admitted for percutaneous coronary intervention (nϭ45). B, ADP-induced binding of 9E18 to platelets was measured on blood samples (PRP) from normal subjects and patients with CAD treated by clopidogrel (nϭ26). Results are expressed as the ratio between the levels of 9E18 binding to ADP-stimulated/nonstimulated sam-plesϫ100. C, ADP-induced 9E18 binding to platelets of patients treated by clopidogrel was plotted against corresponding data of the vasodilatator-stimulated phosphoprotein (VASP) phosphorylation assay. PRI indicates platelet reactivity index. signaling unit. 22, 24 Recent studies have provided evidence that Lyn, a Src family kinase constitutively bound to the Pro-rich motif of the GPVI cytoplasmic domain, is in an activated state 25 and that CD148, a Tyr phosphatase, maintains a pool of active Src family kinases. 20 Consistent with the inhibition of collagen-induced platelet activation, 19 GPVI dimerization was blocked by PAO, a commonly used inhibitor of Tyr phosphatases. 26 Protein disulfide isomerase inhibition by PAO was ruled out by the absence of effect of bacitracin (3 mol/L) on 9E18 binding (data not shown).
Interestingly, GPVI dimerization is controlled by the intracellular cAMP concentration, as indicated by the inhibition of 9E18 binding to resting as well as to ADP-, TRAP-, or PMA-activated platelets by PGE1 or forskolin. Increased concentrations of intracellular cAMP induce potent inhibition of platelet functions. 27 The activity of adenylate cyclase is controlled by Gi-and Gs-coupled receptors, and indeed, opposite effects were produced by activation of the Gicoupled ADP receptor P2Y 12 and activation of the Gscoupled prostacycline receptor on 9E18 binding to platelets. Similarly, it is generally accepted that NO donors inhibit platelet activation and increase intraplatelet cGMP concentration 27 ; accordingly, SNAP also inhibited GPVI dimerization. In healthy vessels, the continual production of prostacyclin and NO by endothelial cells maintains the platelets in a hyporesponsive state, and preservation of GPVI dimerization might contribute to this control process. As soon as the blood is drawn by venipuncture, it is deprived of prostacyclin and NO, and the protection against GPVI dimerization is thus lost. A shift toward GPVI dimerization could also be induced by endothelial dysfunction or the shear-induced vWF/GPIb interaction and may have a priming effect, permitting a more rapid interaction of platelets with collagen as schematized in Figure 6 . Furthermore, traces of ADP or thrombin would amplify this process. One limitation of the present report concerns the signaling mechanism leading to GPVI dimerization that requires additional studies to identify how the Ser/Thr kinases PKA(G) modulate a Tyr phosphatase upstream of GPVI activation.
Another aspect of this work is to propose the measure of dimeric GPVI levels as a new biological marker offering the opportunity to monitor both the activation state of platelets and their reactivity to P2Y 12 antagonists. Surface expression of GPVI has been proposed to represent an indicator for cardiovascular risk because it was reported to be enhanced in patients with acute coronary syndrome, transient ischemic attack, or stroke. 28, 29 Antibodies used in these studies were also raised against dimeric GPVI, and it cannot be excluded that their increased binding to activated platelets could be related to GPVI dimerization. Indeed, the present study, comparing P-selectin exposure and GPVI dimer levels in patients experiencing CAD, demonstrates a good correlation between the 2 markers. GPVI dimerization could be considered an earlier biomarker of platelet activation compared with P-selectin, according to the sequence of events leading to platelet activation. On the other hand, cAMP inhibits GPVI dimerization, whereas antagonists of the ADP receptor P2Y 12 prevent the lowering effect of ADP on cAMP. 30 The measure of ADP-induced binding of 9E18 to platelets could thus represent a new marker estimating simultaneously the biological and the functional efficiency of P2Y 12 antagonists. This is supported by the observations that ADP-induced GPVI dimerization was blocked (1) in vitro by the P2Y 12 antagonist 2MeSAMP and (2) ex vivo, on platelets from patients treated by the thienopyridine clopidogrel. Although numerous platelet function tests have been proposed to identify low responders to P2Y 12 antagonists, there is currently no consensus regarding the most appropriate method. GPVI dimerization could be of great interest because it integrates both the initial activation state and the degree of platelet inhibition. Additional studies are now required to determine whether GPVI dimers represent a reliable predictive marker for the risk of arterial thrombosis, or a reliable marker of the reactivity to P2Y 12 antagonists, by analyzing 9E18 binding to platelets of age-and sex-matched patients.
In this study, using the monoclonal antibody 9E18 as a specific tracer of dimeric GPVI, we have demonstrated that GPVI is maintained in a monomeric form on resting platelets and that GPVI dimerization is an active process that primes platelet interaction with fibrillar collagen and is controlled by cAMP. Consequently, GPVI dimers could represent a new, sensitive, and early marker of platelet responsiveness. Figure 6 . Schematized representation of the mechanism of glycoprotein VI (GPVI) dimerization (adapted from 25 ). On resting platelets, 1 GPVI chain is associated with an FcR␥ homodimer. Complexes assemble as dimers in response to von Willebrand factor and to soluble agonists by a mechanism involving Ser/Thr kinase(s) and Tyr phosphatase(s) and prevented by elevated cAMP or cGMP concentrations. These dimers are competent to bind collagen, leading to the clustering of receptors and consequently to the phosphorylation of the FcR␥ immunoreceptor tyrosine-based activation motif by constitutively GPVI-bound preactivated Lyn and to the downstream signaling cascade. PRD indicates proline rich domain; PY, phosphotyrosine.
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